Yvonne Tan

Yvonne Tan

Auto-generated profile, based on publicly available information

Yvonne Tan

The University of Manchester

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2025 in EULAR Rheumatology Open
Verified
Journal Article
Open access
YTYvonne Tan
Yvonne Tan
GRGeorge Rogers
George Rogers
RSRudresh Shukla
Rudresh Shukla
PHPauline Ho
Pauline Ho
MBMaya H. Buch
Maya H. Buch
To evaluate the proportion of persistent inflammatory refractory rheumatoid arthritis (PIRRA) and noninflammatory refractory rheumatoid arthritis (NIRRA) of difficult-to-treat rheumatoid arthritis (D2T-RA) using musculoskeletal ultrasound (MSUS) and to compare clinical characteristics across PIRRA, NIRRA, and disease-controlled refractory rheumatoid arthritis (RA) subgroups. A retrospective single-centre cohort study identified patients (May 2021 to December 2022) with inadequate response to ≥2 different mechanism of action biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and disease activity score in 28 joints-erythrocyte sedimentation rate (ESR) of >3.2 as European Alliance of Associations for Rheumatology-defined D2T-RA. MSUS classified this group into PIRRA (power Doppler present) or NIRRA (no power Doppler synovitis). A comparator group of controlled refractory RA (≥2 b/tsDMARD failures but sustained low disease activity) was also assessed. Clinical data were collected and analysed. Of the 85 patients, 45 had D2T-RA (25 [56%] PIRRA; 20 [44%] NIRRA), and 40 had controlled refractory RA. PIRRA subgroup had higher C-reactive protein (CRP), but NIRRA subgroup higher ESR. Fibromyalgia was more prevalent in PIRRA and NIRRA than that in controlled refractory RA (48%, 40%, and 17.5%, respectively; P = .02). Nearly half of patients in the controlled refractory group (17/37 [46%]) had subclinical synovitis on MSUS. Rates of radiographic erosions were similar across PIRRA, NIRRA, and controlled refractory groups. MSUS-based stratification of D2T-RA into PIRRA and NIRRA reveals distinct associations to CRP and ESR and comparable chronic pain. Subclinical inflammation is present even in ostensibly controlled disease, suggesting risk of re-falling into an active D2T-RA state. Identifying such subphenotypes can inform on monitoring strategies, support mechanistic investigation, and enable more targeted treatments to improve outcomes of D2T-RA.

9 November 2026 in medRxiv
Verified
Preprint
Open access
PDF file
RHRyan Malcolm Hum
Ryan Malcolm Hum
MCMaria Christofi
Maria Christofi
SSSamantha L Smith
Samantha L Smith
YTYvonne Tan
Yvonne Tan
RSRudresh Shukla
Rudresh Shukla
PMPaul Martin
Paul Martin
Background: Synovial inflammation in psoriatic arthritis (PsA) lacks a validated histological classification framework. Current approaches apply rheumatoid arthritis (RA) synovial pathotypes to PsA, which overlooks immunobiological differences between the diseases and limits the predictive power of tissue stratification. We aimed to define data-driven, PsA-specific synovial pathotypes to facilitate tissue-driven precision medicine. Methods: In this cross-sectional study, ultrasound-guided synovial biopsies were obtained from 61 patients with PsA (n=22), seropositive RA (n=23), seronegative RA (n=10), and other inflammatory arthritides (n=6). Sections underwent multi-modal staining, including H&E, picrosirius red, and immunohisto-chemistry for CD3, CD20, CD68, CD138, and CD31. Whole-slide digital image analysis and automated pixel classifiers quantified cellular and stromal metrics. Unsupervised hierarchical clustering identified intrinsic PsA pathotypes, which were correlated with clinical disease activity, radiographic osteoarthritis (OA), and longitudinal treatment responses. Findings: While a subset of PsA patients shared an inflammatory signature with seropositive RA, unsupervised clustering of the PsA cohort revealed three distinct, novel pathotypes: ‘Dense Myeloid’ (macrophage-driven), ‘Fibro-Stromal’ (fibrosis and pauci-immune), and ‘Angio-Lymphoid’ (hypervascular with significant CD138 + plasma cell infiltration). Pathotypes were independent of treatment and concurrent radiographic knee OA. The Fibro-Stromal pathotype correlated with significantly higher cutaneous psoriasis severity. Longitudinally, patients with the Fibro-Stromal pathotype exhibited a trend toward lower treatment response (44%) following standard interventions (methotrexate or TNF inhibitors) compared to the Dense Myeloid (50%) and Angio-Lymphoid (80%) pathotypes. Interpretation: We present the first computationally derived synovial pathotypes specific to PsA, revealing distinct plasma cell and fibrotic architectures not captured by RA-centric models. To enable clinical translation, we distilled these findings into a pragmatic, four-marker diagnostic decision tree (CD31, CD68, CD138, and picrosirius red) designed for routine histopathology workflows, providing a staging ground for biomarker-stratified clinical trials in PsA. Funding: Funding from the NIHR Biomedical Research Centre: Manchester, Arthritis UK, the Wellcome Trust, Brit-PACT, the National Psoriasis Foundation, and the Medical Research Council. Research in context: Evidence before this study: The potential clinical utility of tissue-based patient stratification is well established in rheumatoid arthritis (RA), where baseline synovial pathotypes (lympho-myeloid, diffuse-myeloid, and pauciimmune) have guided targeted biologic therapy in landmark precision medicine trials. However, psoriatic arthritis (PsA) exhibits a fundamentally distinct synovial microenvironment, characterised by unique vascular architecture, altered stromal fibroblast phenotypes, and distinct immune infiltrates intertwined with the IL-23/IL-17 cytokine axis. Consequently, attempting to classify PsA synovial tissue using established RA-derived scoring systems risks misrepresenting intrinsic disease biology. There is currently no validated, disease-specific histological classification system for PsA, which forces therapeutic decision-making to rely on an empirical, trial-and-error approach rather than underlying target tissue pathobiology. Added value of this study: To our knowledge, this is the first study to define data-driven, computationally derived synovial pathotypes entirely specific to PsA. By leveraging multi-modal digital pathology and unsupervised machine learning, we deconstructed the PsA synovium into three biologically distinct pathotypes: Dense Myeloid, Fibro-Stromal, and Angio-Lymphoid. We demonstrated that the highly inflammatory PsA microenvironment is distinctly driven by CD138 + plasma cells rather than the CD20 + B cells typically observed in RA. Furthermore, we identified a striking tissue-level divergence: patients with the highly fibrotic, pauci-immune Fibro-Stromal pathotype exhibited the most severe cutaneous psoriasis and demonstrated a trend toward higher failure rates on standard therapies, independent of concurrent osteoarthritis. Crucially, we translated these high-dimensional computational findings into a pragmatic, four-marker diagnostic decision tree (incorporating CD31, CD68, CD138, and picrosirius red). Implications of all the available evidence: This study establishes that PsA synovial pathology requires a dedicated, disease-specific classification framework. The proposed diagnostic decision tree can be integrated into routine clinical histopathology workflows without the immediate need for advanced spatial or single-cell transcriptomics. Furthermore, the correlation between the Fibro-Stromal pathotype, severe skin disease, and poor joint response to standard therapies provides a biological rationale for stratifying this specific subgroup towards early IL-17 or IL-23 inhibitor intervention alongside conventional synthetic disease-modifying antirheumatic drugs. Ultimately, these novel PsA pathotypes provide the vital staging ground required to design and execute biomarker-stratified, tissue-driven clinical trials, paving the way for precision medicine in PsA.

7 November 2026 in EULAR Rheumatology Open
Verified
Journal Article
Open access
YTYvonne Tan
Yvonne Tan
RHRyan Malcolm Hum
Ryan Malcolm Hum
ACAnnie Cheung
Annie Cheung
MLMaana Layeghi
Maana Layeghi
RSRudresh Shukla
Rudresh Shukla
MBMaya H Buch
Maya H Buch